Prime Medicine, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-06: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-06 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-07 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-23 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-23 DEF 14A | Aggt Err Compensation Not Yet Determined | RestatementDate: 2023-10-02 | 2025-01-01..2025-12-31 | The compensation recovery policy provides that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover any incentive-based compensation that was based upon the … |
| 2026-04-23 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | We have adopted an Equity Award Grant Policy that sets forth the process and timing for us to follow when we grant equity awards for shares of our common stock to our employees or advisors or consultants (other than our non-employee directors) pursuant to our equity compensation plans. All grants of… | |
| 2026-04-23 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | Generally, equity awards are granted on the following regularly scheduled basis as set forth in the Equity Award Grant Policy: (a) equity awards granted in connection with the hiring of a new employee or the promotion of an existing employee or the engagement of a new consultant will generally be gr… | |
| 2026-04-23 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-23 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | Our Board, compensation committee and Chief Executive Officer do not take into account any material nonpublic information when determining the timing and terms of equity awards. We do not time our equity award grants either to take advantage of a depressed stock price, or an anticipated increase in … | |
| 2026-04-23 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-23 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Table | 2025-01-01..2025-12-31 | The following table contains information required by Item 402(x)(2) of Regulation S-K about stock options granted to our NEOs in the last completed fiscal year during the period beginning four business days before and ending one business day after the filing of our Annual Report on Form 10-K, our Qu… | |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Reine | 2025-02-27 | Allan Reine, M.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Reine | 2025-02-27 | 275,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Reine | 2025-02-27 | 2.42 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Reine | 2025-02-27 | $471.60K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Reine | 2025-02-27 | 0.04 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Lee | 2025-02-27 | Ann Lee, Ph.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Lee | 2025-02-27 | 275,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Lee | 2025-02-27 | 2.42 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Lee | 2025-02-27 | $471.60K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Lee | 2025-02-27 | 0.04 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Duffield | 2025-02-27 | Jeremy Duffield, M.D., Ph.D., FRCP |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Duffield | 2025-02-27 | 275,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Duffield | 2025-02-27 | 2.42 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Duffield | 2025-02-27 | $471.60K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Duffield | 2025-02-27 | 0.04 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Gottesdiener | 2025-02-28 | Keith Gottesdiener, M.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Gottesdiener | 2025-02-28 | 500,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Gottesdiener | 2025-02-28 | 2.52 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Gottesdiener | 2025-02-28 | $892.20K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Gottesdiener | 2025-02-28 | 0.04 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Reine; us-AwardType: us-EmployeeStockOption | 2025-05-19 | Allan Reine, M.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Reine; us-AwardType: us-EmployeeStockOption | 2025-05-19 | 2,000,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Reine; us-AwardType: us-EmployeeStockOption | 2025-05-19 | 1.34 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Reine; us-AwardType: us-EmployeeStockOption | 2025-05-19 | $1.91M |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Reine; us-AwardType: us-EmployeeStockOption | 2025-05-19 | -0.16 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Reine; us-AwardType: us-StockAppreciationRightsSARS | 2025-05-19 | Allan Reine, M.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Reine; us-AwardType: us-StockAppreciationRightsSARS | 2025-05-19 | 500,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Reine; us-AwardType: us-StockAppreciationRightsSARS | 2025-05-19 | 1.34 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Reine; us-AwardType: us-StockAppreciationRightsSARS | 2025-05-19 | $0.00 |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Reine; us-AwardType: us-StockAppreciationRightsSARS | 2025-05-19 | -0.16 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Reine | 2025-08-01 | Allan Reine, M.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Reine | 2025-08-01 | 850,000 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Reine | 2025-08-01 | 4.04 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Reine | 2025-08-01 | $445.80K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Reine | 2025-08-01 | 0.08 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Lee; us-AwardType: us-EmployeeStockOption | 2025-08-01 | Ann Lee, Ph.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Lee; us-AwardType: us-EmployeeStockOption | 2025-08-01 | 180,995 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Lee; us-AwardType: us-EmployeeStockOption | 2025-08-01 | 4.04 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Lee; us-AwardType: us-EmployeeStockOption | 2025-08-01 | $197.79K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Lee; us-AwardType: us-EmployeeStockOption | 2025-08-01 | 0.08 |
| 2026-04-23 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: Lee; us-AwardType: us-StockAppreciationRightsSARS | 2025-08-01 | Ann Lee, Ph.D. |
| 2026-04-23 DEF 14A | Award Undrlyg Securities | Individual: Lee; us-AwardType: us-StockAppreciationRightsSARS | 2025-08-01 | 180,995 |
| 2026-04-23 DEF 14A | Award Exrc Price | Individual: Lee; us-AwardType: us-StockAppreciationRightsSARS | 2025-08-01 | 4.04 |
| 2026-04-23 DEF 14A | Award Grant Date Fair Value | Individual: Lee; us-AwardType: us-StockAppreciationRightsSARS | 2025-08-01 | $120.69K |
| 2026-04-23 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: Lee; us-AwardType: us-StockAppreciationRightsSARS | 2025-08-01 | 0.08 |
| 2026-03-03 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-03 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-03 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-03 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-03 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2025-11-07 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-07 10-Q | Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-07 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-07 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-08-07 10-Q | Non Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-07 10-Q | Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-07 10-Q | Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-08-07 10-Q | Non Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-05-08 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-08 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-08 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-08 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-02-28 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-02-28 10-K | Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-02-28 10-K | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-02-28 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-02-28 10-K | Insider Trading Policies Proc Adopted | 2024-01-01..2024-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |